Methods for treating HCV
The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV patient, wherein said treatment lasts for 8 weeks and does not include administration of either interferon or ribavirin to said patient, and said at least two DAAs comprise PSI-7977 and an HCV NS5A inhibitor, and wherein said patient is a treatment-naïve patient infected with HCV genotype 1.
2. The method of claim 1 , wherein said HCV NS5A inhibitor is Compound 4
3. The method of claim 1 , wherein said PSI-7977 is administered at a dose of 400 mg once daily.
4. The method of claim 1 , wherein said PSI-7977 and said HCV NS5A inhibitor are co-formulated in a single composition and administered once daily.
5. A method of treatment for HCV, comprising administering at least two DAAs to a patient infected with HCV genotype 1, wherein said treatment lasts for 6 or 7 weeks and does not include administration of either interferon or ribavirin to said patient, and said at least two DAAs comprise PSI-7977, an HCV NS5A inhibitor and another DAA.
6. The method of claim 5 , wherein said another DAA is Compound 1
and said HCV NS5A inhibitor is Compound 4
7. The method of claim 5 , wherein said PSI-7977 is administered at a dose of 400 mg once daily.
8. The method of claim 5 , wherein said another DAA is an HCV protease inhibitor.
9. The method of claim 5 , wherein said another DAA is an HCV polymerase inhibitor.
10. The method of claim 5 , wherein said patient is a treatment naïve patient.
11. The method of claim 5 , wherein said patient is an interferon non-responder.